MAFLD patients exhibited higher median body mass index (BMI) (25.3 kg/m2 vs. 23.5 kg/m2, p < 0.001), increased prevalence of type 2 diabetes mellitus (33.0% vs. 12.0%, p = 0.019), greater metabolic dysregulation (63.0% vs. 17.0%, p < 0.001), and elevated alanine aminotransferase (ALT) levels (38.0 IU/L vs. 32.0 IU/L, p = 0.045) compared to non-MAFLD patients. Here, GPT is linked to type 2 diabetes mellitus.